Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation

Liver Transplantation

Volumn 21, Issue 3, 2015, Pages 300-307

  Wong, Florence ^a   Leung, Wesley ^a   Al Beshir, Mohammed ^a   Marquez, Max ^b   Renner, Eberhard L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FRESH FROZEN PLASMA; MIDODRINE; OCTREOTIDE;

ADULT; ARTICLE; BACTERIAL PERITONITIS; CREATININE BLOOD LEVEL; DEATH; DEMOGRAPHY; DIALYSIS; FEMALE; FOLLOW UP; HEPATORENAL SYNDROME; HEPATORENAL SYNDROME TYPE 1; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPTICEMIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; ADVERSE EFFECTS; CANADA; CONVALESCENCE; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TIME TO TREATMENT;

FEMALE; HEPATORENAL SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ONTARIO; PATIENT SELECTION; RECOVERY OF FUNCTION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84923649524     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24049     Document Type: Article

References (26)

1. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.
2. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-1289.
3. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al.; for TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.
4. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.; for Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
5. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56:1293-1298.
6. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 2012;9: 382-391.
7. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991;51:428-430.
8. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006;21:478-482.
9. Meyrier A, Hill GS, Simon P. Ischemic renal diseases: new insights into old entities. Kidney Int 1998;54:2-13.
10. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010;52:605-613.
11. Northup PG, Argo CK, Bakhru MR, Schmitt TM, Berg CL, Rosner MH. Pretransplant predictors of recovery of renal function after liver transplantation. Liver Transpl 2010; 16:440-446.
12. Ruiz R, Kunitake H, Wilkinson AH, Danovitch GM, Farmer DG, Ghobrial RM, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006;141:735-741.
13. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008;8:2243-2251.
14. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011;60:702-709.
15. Hadengue A, Lebrec D, Moreau R, Sogni P, Durand F, Gaudin C, et al. Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology 1993;17:175-178.
16. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med 1973;289:1155-1159.
17. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-365.
18. Cassinello C, Moreno E, Gozalo A, Ortuño B, Cuenca B, Solís-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179-186.
19. Lameire NH, Vanholder R. Pathophysiology of ischaemic acute renal failure. Best Pract Res Clin Anaesthesiol 2004;18:21-36.
20. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001;281:F887-F899.
21. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
22. Xu X, Ling Q, Zhang M, Gao F, He Z, You J, Zheng S. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation 2009;87:1514-1519.
23. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.; for Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17:1328-1332.
24. Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40: 140-146.
25. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al. Initial report of a large, randomized, double-blind, placebo controlled, phase 3 trial of terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (HRS-1): the REVERSE study [abstract]. Hepatology 2014;60(suppl):255A.
26. Chok KS, Fung JY, Chan SC, Cheung TT, Sharr WW, Chan AC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl 2012;18:779-785.